134 related articles for article (PubMed ID: 28474336)
1. Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.
Lee S; Day NS; Miles RR; Perkins SL; Lim MS; Ayello J; van de Ven C; Harrison L; El-Mallawany NK; Goldman S; Cairo MS
Br J Haematol; 2017 May; 177(4):601-611. PubMed ID: 28474336
[TBL] [Abstract][Full Text] [Related]
2. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
Miles RR; Cairo MS; Satwani P; Zwick DL; Lones MA; Sposto R; Abromovitch M; Tripp S; Angiolillo AL; Roman E; Davenport V; Perkins SL
Br J Haematol; 2007 Aug; 138(4):506-12. PubMed ID: 17659054
[TBL] [Abstract][Full Text] [Related]
5. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization.
Wessendorf S; Schwaenen C; Kohlhammer H; Kienle D; Wrobel G; Barth TF; Nessling M; Möller P; Döhner H; Lichter P; Bentz M
Oncogene; 2003 Mar; 22(9):1425-9. PubMed ID: 12618769
[TBL] [Abstract][Full Text] [Related]
6. Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma.
El-Mallawany NK; Day N; Ayello J; Van de Ven C; Conlon K; Fermin D; Basrur V; Elenitoba-Johnson K; Lim M; Cairo MS
Eur J Cancer; 2015 Jan; 51(1):92-100. PubMed ID: 25466511
[TBL] [Abstract][Full Text] [Related]
7. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
Kodet R; Mrhalová M; Stejskalová E; Kabícková E
Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
[TBL] [Abstract][Full Text] [Related]
8. The RB (pRb2/p16) and p53 (p14/p53/p21) tumor-suppressor pathways in endemic Burkitt lymphoma.
Kalungi S; Wabinga H; Bostad L
J Pediatr Hematol Oncol; 2011 Mar; 33(2):e54-9. PubMed ID: 21127431
[TBL] [Abstract][Full Text] [Related]
9. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.
Wever CM; Geoffrion D; Grande BM; Yu S; Alcaide M; Lemaire M; Riazalhosseini Y; Hébert J; Gavino C; Vinh DC; Petrogiannis-Haliotis T; Dmitrienko S; Mann KK; Morin RD; Johnson NA
Leuk Lymphoma; 2018 Sep; 59(9):2159-2174. PubMed ID: 29295643
[TBL] [Abstract][Full Text] [Related]
10. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
[TBL] [Abstract][Full Text] [Related]
11. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
13. Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.
Giulino-Roth L; Goldman S
Br J Haematol; 2016 May; 173(4):531-44. PubMed ID: 26996160
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.
Miles RR; Arnold S; Cairo MS
Br J Haematol; 2012 Mar; 156(6):730-43. PubMed ID: 22260323
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
Atallah-Yunes SA; Habermann TM; Khurana A
Br J Haematol; 2024 Jun; 204(6):2165-2172. PubMed ID: 38577716
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue.
Masqué-Soler N; Szczepanowski M; Kohler CW; Aukema SM; Nagel I; Richter J; Siebert R; Spang R; Burkhardt B; Klapper W
Br J Haematol; 2015 Nov; 171(4):501-8. PubMed ID: 26218299
[TBL] [Abstract][Full Text] [Related]
17. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
18. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
19. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
[TBL] [Abstract][Full Text] [Related]
20. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
